Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

Scott E. Woodman, Jonathan C. Trent, Katherine Stemke-Hale, Alexander J. Lazar, Sabrina Pricl, Giovanni M. Pavan, Maurizio Fermeglia, Y. N.Vashisht Gopal, Dan Yang, Donald A. Podoloff, Doina Ivan, Kevin B. Kim, Nicholas Papadopoulos, Patrick Hwu, Gordon B. Mills, Michael A. Davies

Research output: Contribution to journalArticle

141 Scopus citations

Abstract

Point mutations in the KIT receptor tyrosine kinase gene have recently been identified in mucosal, acral lentiginous, and chronically sun-damaged melanomas. We have identified the first human melanoma cell line with an endogenous L576P mutation, the most common KIT mutation in melanoma ( 30-40%). In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors effective in nonmelanoma cells with other KIT mutations. However, the viability of the mutant cells was reduced by dasatinib at concentrations as low as 10 nM (P = 0.004). Molecular modeling studies found that the L576P mutation induces structural changes in KIT that reduce the affinity for imatinib (ΔΔGbind = -2.52 kcal/mol) but not for dasatinib (ΔΔGbind = +0.32 kcal/mol). Two metastatic melanoma patients with the L576P KIT mutation were treated with dasatinib, including one patient previously treated with imatinib. Both patients had marked reduction (>50%) and elimination of tumor F18-fluorodeoxyglucose (FDG)-avidity by positron emission tomography (PET) imaging after dasatinib treatment. These data support the selective inhibitory effect of dasatinib against cells harboring the most common KIT mutation in melanoma, and thus has therapeutic implications for acrallentiginous, chronic sun-damaged, and mucosal melanomas.

Original languageEnglish (US)
Pages (from-to)2079-2085
Number of pages7
JournalMolecular cancer therapeutics
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates'. Together they form a unique fingerprint.

  • Cite this

    Woodman, S. E., Trent, J. C., Stemke-Hale, K., Lazar, A. J., Pricl, S., Pavan, G. M., Fermeglia, M., Gopal, Y. N. V., Yang, D., Podoloff, D. A., Ivan, D., Kim, K. B., Papadopoulos, N., Hwu, P., Mills, G. B., & Davies, M. A. (2009). Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Molecular cancer therapeutics, 8(8), 2079-2085. https://doi.org/10.1158/1535-7163.MCT-09-0459